About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETED

Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy

Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy

NCT02403869•Celgene

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Breast Neoplasms

Locations

29

Spain

Locations (29)

Hospital Juan Ramón Jiménez

Huelva, Andalusia, Spain

Hospital Virgen de Valme

Seville, Andalusia, Spain

Hospital Virgen del Rocío

Seville, Andalusia, Spain

Hospital Miguel Servet

Zaragoza, Aragon, Spain

Hospital Universitario Lozano Blesa

Zaragoza, Aragon, Spain

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, Spain

Key Dates

Start Date

March 12, 2014

Primary Completion Date

January 31, 2019

Completion Date

January 31, 2019

Last Updated

June 30, 2022

Related Studies

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

RECRUITINGPhase 3

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176

Breast Neoplasms

RECRUITINGPhase 2

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635

Breast NeoplasmsBreast Cancer

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

NCT07003841

Breast Neoplasms

Dissemination of BREASTChoice AIM1-B

NCT07396766

Breast CancerBreast Neoplasms

Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B

NCT06443645

Breast Neoplasms

View all related studies

Sponsors

Lead Sponsor

Celgene

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 30, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions